Alkermes plc. Payments of Debt Restructuring Costs
Alkermes plc. (ALKS) reported Payments of Debt Restructuring Costs of $2.25 million for the 12-month period ending 2018-12-31, per its 10-K filed 2019-02-15.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsOfDebtRestructuringCosts · last filed 2019-07-25
- Alkermes plc. payments of debt restructuring costs for the quarter ending 2018-12-31 was $0.00.
- Alkermes plc. payments of debt restructuring costs for the quarter ending 2018-09-30 was $0.00.
- Alkermes plc. payments of debt restructuring costs for the quarter ending 2018-06-30 was $411.00K.
- Alkermes plc. payments of debt restructuring costs for the quarter ending 2018-03-31 was $1.84M.
- Alkermes plc. payments of debt restructuring costs for fiscal 2018 was $2.25M.
| Period end | Payments of Debt Restructuring Costs 3 month | Payments of Debt Restructuring Costs 6 month | Payments of Debt Restructuring Costs 9 month | Payments of Debt Restructuring Costs 12 month |
|---|---|---|---|---|
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-15 | $0.00 derived: sum of 2 quarters · filed 2019-02-15 | $411.00K derived: sum of 3 quarters · filed 2019-07-25 | $2.25M 10-K · filed 2019-02-15 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-23 | $411.00K derived: sum of 2 quarters · filed 2019-07-25 | $2.25M 10-Q · filed 2018-10-23 | |
| 2018-06-30 | $411.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-25 | $2.25M 10-Q · filed 2019-07-25 | ||
| 2018-03-31 | $1.84M 10-Q · filed 2019-04-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |